Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes
Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic vari...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2017
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23850
- Acceso en línea:
- https://doi.org/10.1111/dom.12930
https://repository.urosario.edu.co/handle/10336/23850
- Palabra clave:
- Glucose
Hemoglobin a1c
Insulin
Lixisenatide
Placebo
Antidiabetic agent
Glucagon like peptide 1 receptor
Glycosylated hemoglobin
Insulin
Lixisenatide
Peptide
Article
Body mass
Clinical effectiveness
Clinical evaluation
Disease duration
Drug efficacy
Endocrine function
Follow up
Glucose blood level
Glycemic variability
Hemoglobin blood level
Human
Hypoglycemia
Major clinical study
Multicenter study (topic)
Non insulin dependent diabetes mellitus
Phase 3 clinical trial (topic)
Randomized controlled trial (topic)
Agonists
Analysis
Blood
Blood glucose monitoring
Chemically induced
Clinical trial
Cohort analysis
Combination drug therapy
Controlled study
Double blind procedure
Drug resistance
Hyperglycemia
Hypoglycemia
Intention to treat analysis
Metabolism
Middle aged
Non insulin dependent diabetes mellitus
Pathophysiology
Phase 3 clinical trial
Randomized controlled trial
Reproducibility
Severity of illness index
Blood glucose
Blood glucose self-monitoring
Cohort studies
Double-blind method
Drug resistance
Follow-up studies
Glucagon-like peptide-1 receptor
Glycated hemoglobin a
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic agents
Insulin
Intention to treat analysis
Middle aged
Peptides
Reproducibility of results
Severity of illness index
Glycaemic variability
Insulin
Lixisenatide
Type 2 diabetes
type 2
combination
human
human
Glp1r protein
Hemoglobin a1c protein
Diabetes mellitus
Drug therapy
- Rights
- License
- Abierto (Texto Completo)
Summary: | Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin. The main outcome GV measures were standard deviation (s.d.), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG) level, area under the curve for fasting glucose (AUC-F), and high (HBGI) and low blood glucose index (LBGI). The change in GV metrics over 24 weeks and relationships among baseline GV, patient characteristics and outcomes were assessed. Data were pooled from 1198 patients (665 LIXI, 533 placebo). Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged. Higher baseline GV measures correlated with older age, longer type 2 diabetes duration, lower body mass index, higher baseline glycated/haemogobin, greater reduction in postprandial glucose (PPG) level, and higher rates of symptomatic hypoglycaemia. These data show that LIXI added to basal insulin significantly reduced GV and PPG excursions vs placebo, without increasing the risk of hypoglycaemia (LBGI). © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley and Sons Ltd. |
---|